

2015


KRN7000

α – Galactosyl Ceramide

For more information : http://www.funakoshi.co.jp/exports_contents/46127

α -Galactosylceramide (α -Gal-Cer; KRN7000) was developed by Kyowa Hakko Kirin Company, as a biological response modifier. The α -Gal-Cer was isolated from an extract of the marine sponge, *Agelas mauritanus*, as an active substance which has galactose combined with ceramide in an α -configuration. α -Gal-Cer (KRN7000), a chemically synthesized α -Galactosylceramide, is a specific ligand for human and mouse natural killer T (NKT) cells. α -Gal-Cer exhibits potent antitumor activity in various kinds of *in vitro* murine experimental models including subcutaneously implanted model and metastatic models in the liver and lung. In the liver metastatic models, treatment with α -Gal-Cer suppressed the growth of tumors and prolonged the survival term of tumor-bearing mice. α -Gal-Cer has been reported to show various immunological influence in infectious disease, autoimmune disease, and graft versus host disease in mice.

Structure



For the research of...

- Anti-tumor response
- Anti-autoimmune response
- Anti-inflammation

through NKT – Dendritic Cells immune system

Citation

Chang CH *et al.*, PLoS One. 2015 Mar 25;10(3):e0121320.
Ando *et al.*, Oncol Rep. 2015 Feb;33(2):826-32.
Hasegawa *et al.*, Anticancer Res. 2014 Jul;34(7):3411-7.
Nakamura *et al.*, J Control Release. 2013 Oct 28;171(2):216-24
JJ O'Konek *et al.*, Clin Cancer Res. 2013 Aug 15;19(16):4404-11
Thomsen MK *et al.*, J Clin Invest. 2013 Dec;123(12):5258-68
Bjordahl RL *et al.*, PLoS One. 2012;7(8):e42635.

... and more!

Our KRN7000 is used on Proimmune's CD1d tetramers!



Note: Alpha-GalCer (KRN7000) is for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of Kyowa Hakko Kirin Company.

Kyowa Hakko Kirin Company has issued a worldwide license for KRN7000 research to Funakoshi Company.

Product Information

[Manufacture : KRN]

Product Name	Size	Catalog #	Storage
α -Galactosylceramide < α -Gal-Cer>, <KRN7000>	1 mg	KRN7000	-20°C

2015


7DW8-5

For more information : http://www.funakoshi.co.jp/exports_contents/46127

There are a number of glycolipids synthesized, some of which are analogs of α -galactosyl ceramide (α -Gal-Cer), a marine sponge lipid that is the most extensively studied CD1d ligand to date. These compounds were tested for their ability to stimulate human invariant natural killer T (iNKT) cell lines, secretion of key cytokines such as IFN- γ and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T-cell receptor. A lead compound 7DW8-5, emerged from these studies and this glycolipid exhibits a stronger adjuvant effect than α -Gal-Cer in various HIV vaccine platforms in mice. 7DW8-5 also provides a protective adjuvant effect with a candidate malaria vaccine when tested in mice infected with malaria parasites. While the majority of the studies performed focus on the potential of the glycolipids as a vaccine adjuvant, it is foreseeable that the compounds could also be used as a potential immunotherapeutic to treat cancer, infectious diseases, and autoimmune diseases.

※ This product is licensed by The Rockefeller University.

Structure



For the research of...

- Anti-tumor response
- Anti-autoimmune response
- Anti-inflammation

through NKT – Dendritic Cells immune system

Citation

- Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong C-H, Ho DD, Tsuji M. 2010. Design of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc. Natl. Acad. Sci. USA. 107: 13010-13015.
- Padte NN, Li X, Tsuji M, Vasan S. 2011. Clinical Development of a Novel CD1d-binding NKT Cell Ligand as a Vaccine Adjuvant. Clin. Immunol. 140: 142-151.

Product Information

[Manufacture : FRK]

Product Name	Size	Catalog #	Storage
7DW8-5	1 mg	7DW8-5	-20°C

NOTE

※ All products here are research use only, not for diagnostic use.
※ Specs might be changed for improvement without notice.

※ Company name and product name are trademark or registered mark.
※ Please contact your local distributors for orders, quote request and inquiry.

Your Local Distributor



PELOBiotech GmbH

Address: Am Klopferspitz 19
82152 Planegg / Martinsried Germany
Phone : +49(0)89-517 286 59-0
Fax : +49(0)89-517 286 59-88
Email : info@pelobiotech.com



funakoshi Co., Ltd.

Address: 9-7 Hongo 2-Chome, Bunkyo-ku,
Tokyo 113-0033 JAPAN
Phone : +81-3-5684-6296
Fax : +81-3-5684-6297
Email : export@funakoshi.co.jp